Agilent Technologies Inc. agreed to acquire privately held Biocare Medical, which makes instruments and materials used in ...

Agilent Technologies Inc. shares are up during Monday’s premarket session as the company announces the acquisition of Biocare Medical for around $950 million. Synergies Biocare Medical has been a ...

Agilent Technologies, Inc. (NYSE:A) is one of the stocks on which Jim Cramer expressed his thoughts. A caller asked if the ...

Detailed price information for Agilent Technologies (A-N) from The Globe and Mail including charting and trades.

By Sahil Pandey March 9 (Reuters) - Life sciences firm Agilent Technologies said on Monday that it will acquire privately held clinical pathology firm Biocare Medical in an all-cash deal valued at ...

Agilent Technologies said that it will acquire privately held clinical pathology firm Biocare Medical in an all-cash deal of $950 million ...

Citi swept through its life science tools and diagnostics coverage on Wednesday, opening a 90-day upside catalyst watch on Agilent Technologies (NYSE:A) while trimming its price target on Icon PLC ...

Biocare has been under the stewardship of VC firms Excellere Partners and GHO Capital since 2021, achieving revenue of $90m in 2025.

Agilent acquires Biocare for $950M to boost pathology/cancer diagnostics and recurring revenue. Click here to read an analysis of A stock now.

Detailed price information for Agilent Technologies (A-N) from The Globe and Mail including charting and trades.

Agilent Technologies stock overview Agilent Technologies (A) has drawn investor attention after recent share performance, with the stock showing negative returns over the past month and past 3 months ...

Agilent Technologies has agreed to buy pathology company Biocare Medical in an all-cash deal valued at $950 million that bolsters its immunohistochemistry offering.